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FACTORS ASSOCIATED WITH INITIATION OF HIGH-DOSE DULOXETINE AMONG
PATIENTS WITH OSTEOARTHRITIS
Peng X1, Wu N2, Andrews JS1, Chen SY2, Boulanger L2
1Eli Lilly and Company, Inc., Indianapolis, IN, USA, 2United BioSource Corporation, Lexington,
MA, USA
OBJECTIVES: To identify pre-treatment predictors associated with high initiating
doses of duloxetine therapy for patients with osteoarthritis (OA). METHODS: Pa-
tients with OA diagnosis who initiated duloxetine between November 1, 2010 to
March 31, 2011 were selected from a medical and pharmacy claims database. The
dispense date of the first duloxetine prescription preceded by at least a 90-day gap
in medication supply was defined as the index date. Comorbidities and prior med-
ication use were assessed during six months prior to the index date. Multiple
logistic regression models were performed to identify predictors of initiating du-
loxetine: 1) 60mg versus 60mg, and 2) 60mg versus 60mg. RESULTS: A total of
2034OApatients (mean age 63.7 years; 75.5% female)who initiated duloxetinewere
identified. Common comorbidities included hypertension (57.4%), depression
(35.3%) and diabetes (29.4%). Common pain medications used prior to duloxetine
initiation were opioids (71.5%, 69.4% and 16.5% on short- and long-acting opioids,
respectively), antidepressants (52.4%), and non-steroidal anti-inflammatory drug
(NSAIDs, 36.5%). Of the duloxetine initiators, 50.3% started on 60mg, 38.7% 60mg
and 10.9% 60mg. Compared to patients 18-44 years old, patients 75 years old
were more likely to start on a dose60mg (Odds Ratio [OR]: 1.89, 95% Confidence
Interval [CI]: 1.19-3.01). Patients with prior use of opioid (OR: 0.75, 95% CI: 0.60-0.94)
or hypertension (OR: 0.74, 95% CI: 0.60-0.92) were less likely to start on 60mg,
whereas patients with prior use of NSAIDs (OR: 1.24, 95% CI: 1.01-1.53) or malig-
nancy (OR: 1.53, 95%CI: 1.06-2.21) weremore likely to start on60mg. Patientswith
prior use of duloxetine (OR: 1.67, 95% CI: 1.08-2.57) or depression (OR: 1.61, 95% CI:
1.12-2.31) were more likely to start on a dose60mg. CONCLUSIONS: Most of the
patients initiated duloxetine at 60mg/day. Presence of selected comorbidities and
prior use of medications were associated with higher starting dose of duloxetine
among OA patients.
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ADHERENCE AND URIC ACID GOAL ATTAINMENT WITH URATE LOWERING
THERAPY IN PATIENTS WITH GOUT
Rashid N1, Cheetham CT2, Niu F1
1Kaiser Permanente Southern California, Downey, CA, USA, 2Kaiser Permanente, Downey, CA,
USA
OBJECTIVES: Evaluate patient and prescriber characteristics associated with gout
patients newly initiating allopurinol; evaluate adherence within this population.
METHODS: Retrospective study of gout patients was conducted using Kaiser Per-
manente Southern California health care data. Patients aged 18 years and older
with a diagnosis of gout (ICD9 274.xx) and allopurinol prescription from January 1,
2007 to June 31, 2010 were included. Incident allopurinol users were defined as
patients that had no allopurinol prescription within 12months prior of the 1st gout
diagnosis (index date). Patients had at least 12 months of follow up after their 1st
allopurinol prescription. Descriptive statistics such as age, gender, race, co-morbid
conditions, concomitant medications, prescriber specialty, and allopurinol dose
adjustment were calculated comparing patients at sUA goal (6mg/dl) or not at
sUA goal. MPR mean and adherence was measured using the medication posses-
sion ratio (MPR) over the followup time period andwas defined as 80%. RESULTS:
A total of 9288 gout patientswere identified as incident allopurinol users (mean age
60 years, men 78%). All patients had at least one comorbid condition with the
following conditions being the most common: hypertension (73%), chronic kidney
disease (32%), and diabetes (25%). Hydrochlorothiazide (21%) and furosemide (17%)
were the most commonly utilized concomitant medications. At the end of obser-
vation, 2,749 patients (30%) were at sUA goal (mean age 63 years, men 71%) versus
6539 patients not at goal (mean age 59 years, men 81%). ThemeanMPR for patients
at goal was 92% versus 77% for patients not at goal. A total of 1793 patients (65%)
were adherent and at goal versus 40% were adherent but not at goal.
CONCLUSIONS: Sixty percent of incident allopurinol users do not have UA goal
attainment and are less adherent. Efforts need to bemade to improve adherence to
better obtain goal attainment.
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DERIVATION OF SEVERITY INDEX FOR RHEUMATOID ARTHRITIS AND ITS
EFFECT ON HEALTH CARE OUTCOMES
Baser O1, Wang L2, Xie L1, Du J3, Wang H4
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research,
Dallas, TX, USA, 3STATinMED Research, Ann Arbor, MI, USA, 4The University of Michigan, Ann
Arbor, MI, USA
OBJECTIVES: To develop a claims-based severity index for rheumatoid arthritis
(RA) using large US claims data. METHODS: Adult patients with at least two RA
diagnoses 2 months apart were identified from a large US claims database (10/1/
2008-09/30/2009). Patients were required to have at least 12 months continuous
health plan enrollment before and after the index date (first RA diagnosis date). A
severity index for rheumatoid arthritis (SIFRA) was developed by calculating a
weighted sum of 47 RA-related indicators including laboratory, clinical and func-
tional status, extra-articular manifestations, surgical history, and medications as-
sessed by an expert Delphi panel of six rheumatologists. Two versions of SIFRA
were derived for patients with and without laboratory information. Correlations
between SIFRA and previously validated claims-based indexes for RA severity (CI-
RAS), and other traditional comorbidity indexes were calculated. The relationship
between SIFRA and heath care costs was also examined using histograms.
RESULTS: The Spearman’s rank correlations between SIFRA and CIRAS were 0.525
for SIFRA without laboratory data and 0.539 for SIFRA with laboratory data. The
correlations between SIFRA and the Charlson Comorbidity Index (0.1503 without,
0.1135 with laboratory data), Elixhauser Index (0.105 without, 0.079 with laboratory
data) and Chronic Disease Score (CDS) (0.255 without, 0.239 with laboratory data)
were low. Histograms showed that patients in the upper tercile of SIFRA incurred
$9,123 more all-cause health care costs and $1,326 more RA-related health care
costs than patients in the lower tercile of SIFRA. CONCLUSIONS: SIFRA was found
to havemoderate correlationswith the previously validated CIRAS score, and dem-
onstrated evidence of being a significant determinant of total and RA-related
health care costs for RA patients. This study suggests that SIFRA could be an im-
portant methodological tool to control for severity in RA-related outcomes re-
search.
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WHY THE FINDINGS OF PUBLISHED RHEUMATOID ARTHRITIS MULTIPLE
TREATMENT COMPARISONS ARE SO DIFFERENT - AN OVERVIEW OF
RECURRENT METHODOLOGICAL SHORTCOMINGS
Thorlund K1, Mills E2
1McMaster University, Hamilton, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada
OBJECTIVES: To methodologically review the published literature on rheumatoid
arthritis multiple treatment comparison meta-analysis (MTCs). To identify meth-
odological issues that can explain the substantial discrepancies in the findings of
these MTCs. METHODS: We searched MEDLINE for rheumatoid arthritis multiple
treatment comparisons. Following the PRISMA guidelines, we extracted a large set
of methodological items from the identified reviews. These included, but were not
limited to, inclusion/exclusion criteria, information sources (e.g., MEDLINE), ap-
proaches to dealing with monotherapies versus combination therapies, ap-
proaches to dealing with potential covariate effect modifiers (i.e., sources of
heterogeneity). RESULTS: We identified 11 published MTC, of which 7 were pub-
lished since 2009. We identified major discrepancies in the inclusion of trials, de-
spite highly similar eligibility criteria and literature searches. The total number of
trials covered among all MTCs was 61. The number of trials, however, included in
the individual MTCs published since 2009 spanned from 15 to 31 – i.e., 25%-50% of
all available trials. We identified inconsistencies in approaches to dealing with
monotherapy and combination therapy trials. Most MTCs lumped the two sets of
trials without either controlling for the effect of concomitant use of disease mod-
ifying anti rheumatic drugs (DMARDs) or separately comparing the effectiveness
estimates in the two. Approximately half of the identified MTCs did not explore
potential sources of heterogeneity. Among those that did, the explored sources
were inconsistent.CONCLUSIONS:Majormethodological shortcomings and incon-
sistencies exist throughout published rheumatoid arthritis MTCs. There are many
lessons to be learned from these previous publications which can potentially
strengthen the current evidence base.
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USE OF COMMON DATA MODEL TO ENABLE MEANINGFUL COMPARISON OF
DISEASE BURDEN AMONG DISPARATE DATABASES
Schneider G1, Powell G2, Reisinger S3
1United BioSource Corporation, Lexington, MA, USA, 2GlaxoSmithKline, RTP, NC, USA, 3United
BioSource Corporation, Harrisburg, PA, USA
OBJECTIVES: Use of a Common Data Model (CDM) to standardize underlying data
assumptions and format enables consistency in the application of research meth-
ods and production of meaningfully comparable results across disparate data
sources. This study compared the baseline disease burden, as measured via a
standardmethod deriving Charlson Comorbidity Index (CCI), which was applied to
multiple observational databases after all source datawas transformed into a stan-
dard CDM format.METHODS: Two unique patient cohorts, 1) newly diagnosed and
treated depression patients (DEP), and 2) newly diagnosed rheumatoid arthritis
patients (RA) were identified using equivalent definitions from multiple claims
databases which had been previously transformed into a standard CDM format.
CCI was calculated for each Cohort using a single SAS macro developed for CCI
derivation using CDM-format data Descriptive information on CCI, in aggregate
and stratified by age category and gender,was compared separately for theDEP and
RA cohorts across all databases. RESULTS: Despite a common data format, consis-
tent cohort definitions, and a single method for CCI derivation, the calculated CCI
varied by asmuch as 20% (RA) and 50% (DEP) across the different databases used for
this study. Gender had little influence on CCI differential. CCI differential generally
decreased with advancing age category for both DEP and RA, with largest differen-
tials exceeding 4-fold in 18-30 age group (DEP) and smallest differentials of 10% in
80 age group (DEP). CONCLUSIONS: Common Data Models provide an efficient
way of enabling meaningful comparisons across disparate data sources. Dispari-
ties in CCI results, despite identical cohort definitions and the application of a
single SAS macro, are likely the result of differences in underlying populations,
data capture process, and/or functional ability and/or incentive to record complete
information in source data. Future research should focus on how each of these
factors may impact disease burden indices.
PMS87
OSTEOARTHRITIS IN FRANCE THE COST OF AMBULATORY CARE IN 2010
Taieb C
CREES PFSA, Boulogne, France
OBJECTIVES: In France, the cost of an osteoarthritic patient has not been estimated
for several years.The aim of the study was to evaluate the annual cost of the
treatment given to osteoarthritic patients by GP.METHODS: The cohort was made
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